KPTI NASDAQ
Karyopharm Therapeutics Inc.
1W: -50.5%
1M: -55.2%
3M: -91.7%
YTD: -88.8%
1Y: -87.1%
3Y: -96.1%
5Y: -99.1%
$0.80
-0.06 (-7.45%)
Weekly Expected Move ±20.4%
$0
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
11 relationships11
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-12-21
Earliest Filing
2026-03-24
Latest Filing
partner: 8
investor: 3
Counterparties (Filed by KPTI)
11 relationshipsCompanies named in KPTI's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| RA Capital Management | — | investor | Investor in private placement securities purchase agreement | 2026-03-24 | View |
| Jefferies LLC | JEF | partner | Placement agent for the private placement | 2026-03-24 | View |
| Piper Sandler & Co. | PIPR | partner | Placement agent for the private placement | 2026-03-24 | View |
| HealthCare Royalty Management, LLC | — | investor | Acted as the investor representative in the Revenue Interest Financing Agreement. | 2025-10-14 | View |
| HCR Karyopharm SPV, LLC | — | investor | Acted as the collateral agent in the Revenue Interest Financing Agreement. | 2025-10-14 | View |
| TCD 234 MA WELLS PROPERTY LLC | — | partner | Landlord in office lease amendment agreement | 2024-11-08 | View |
| AG-JCM Wells Avenue Property Owner, LLC | — | partner | Successor-in-interest to Landlord | 2024-11-08 | View |
| NS Wells Acquisition LLC | — | partner | Successor-in-interest to Landlord | 2024-11-08 | View |
| Taurus Investment Holdings, LLC | — | partner | Manager of Landlord | 2024-11-08 | View |
| Bowditch & Dewey, LLP | — | partner | Legal counsel for Tenant | 2024-11-08 | View |
| Berlin-Chemie AG | — | partner | Entered into a license agreement for the development and commercialization of selinexor products in specific territories | 2021-12-21 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-18 | Bylaws Amendment; Exhibits | View | |
| 2026-09-11 | Material Agreement; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-08-31 | Other Events | View | |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-07-31 | Other Events | View | |
| 2026-07-17 | Officer/Director Change | View | |
| 2026-05-28 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-14 | Earnings Release; Exhibits | View | |
| 2026-03-27 | Other Events | View | |
| 2026-03-24 | Material Agreement; Unregistered Equity Sales; Regulation FD; Other Events; Exhibits | Agreement | View |
| 2026-03-03 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-02-19 | Submission of Matters to a Vote of Security Holders | View | |
| 2026-02-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-14 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Other Events; Fin | Agreement | View |
| 2025-10-08 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Creation of | Agreement | View |
| 2025-09-11 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR